Phase 1/2 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) That is Refractory to or Relapsed After Standard Induction Therapy

Trial Profile

Phase 1/2 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) That is Refractory to or Relapsed After Standard Induction Therapy

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Annamycin (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Moleculin Biotech
  • Most Recent Events

    • 04 Apr 2018 Status changed from not yet recruiting to recruiting, according to the Moleculin Biotech media release.
    • 04 Apr 2018 According to the Moleculin Biotech media release, first two patient enrolled in this study has begun treatment at The University Hospitals Cleveland Medical Center Seidman Cancer Center.
    • 15 Feb 2018 According to a Moleculin Biotech media release, the company is planning to initiate this trial in the United States or Poland in this quarter.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top